Volume 10 Issue 8
Aug.  2019
Turn off MathJax
Article Contents
Zixuan An, Wenxing Lv, Shang Su, Wei Wu, Yu Rao. Developing potent PROTACs tools for selective degradation of HDAC6 protein[J]. Protein&Cell, 2019, 10(8): 606-609. doi: 10.1007/s13238-018-0602-z
Citation: Zixuan An, Wenxing Lv, Shang Su, Wei Wu, Yu Rao. Developing potent PROTACs tools for selective degradation of HDAC6 protein[J]. Protein&Cell, 2019, 10(8): 606-609. doi: 10.1007/s13238-018-0602-z

Developing potent PROTACs tools for selective degradation of HDAC6 protein

doi: 10.1007/s13238-018-0602-z
  • loading
  • [1]
    Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci(Lond) 130:987-1003
    [2]
    Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.J Med Chem 55:9891-9899
    [3]
    Boettcher M, McManus MT (2015) Choosing the right tool for the job:RNAi, TALEN, or CRISPR. Mol Cell 58:575-585
    [4]
    Davisson MT, Bergstrom DE, Reinholdt LG, Donahue LR (2012)Discovery genetics-the history and future of spontaneous mutation research. Curr Protoc Mouse Biol 2:103-118
    [5]
    El-Brolosy MA, Stainier DYR (2017) Genetic compensation:a phenomenon in search of mechanisms. PLoS Genet 13:e1006780
    [6]
    Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738
    [7]
    Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Van Leeuwen FW, Chanan-Khan AA et al(2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281-3290
    [8]
    Lai AC, Crews CM (2017) Induced protein degradation:an emerging drug discovery paradigm. Nat Rev Drug Discov 16:101-114
    [9]
    Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M et al (2012)Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia 26:2326-2335
    [10]
    Miyake Y, Keusch JJ, Wang L, Saito M, Hess D, Wang X, Melancon BJ, Helquist P, Gut H, Matthias P (2016) Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol 12:748-754
    [11]
    Seto E, Yoshida M (2014) Erasers of histone acetylation:the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6:a018713
    [12]
    Sun YH, Zhao XW, Ding N, Gao HY, Wu Y, Yang YQ, Zhao M, Hwang J, Song YG, Liu WL et al (2018) PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 28:779-781
    [13]
    Valenzuela-Fernandez A, Cabrero JR, Serrador JM, SanchezMadrid F (2008) HDAC6:a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18:291-297
    [14]
    Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W (2018)Development of the first small molecule histone deacetylase 6(HDAC6) degraders. Bioorg Med Chem Lett 28:2493-2497
    [15]
    Zhou B, Hu JT, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y et al (2018) Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem 61:462-481
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (1225) PDF downloads(123) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return